MetaCap

Perspective Therapeutics (CATX) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 3.0% versus a loss of 63.9%. Over five years, CATX leads with a -84.6% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $91.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%PDSB+2.97%
+183%+48%-86%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%PDSB-92.26%
+288%+86%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus PDSB key metrics
MetricCATXPDSB
Share price$0.7538$0.7774
Market cap$91.03M$95.39M
1-day change-3.85%-3.70%
YTD return-72.59%+0.96%
1-year return-63.93%+2.97%
5-year return-84.62%-92.46%
EPS (TTM)$-1.25$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-103.12M$-34.50M
52-week high$6.16$1.79
52-week low$0.73$0.195
Distance from 52-week high-87.76%-56.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+478.85%
Average volume2.70M25.64M
Shares outstanding120.76M122.70M
Employees16321
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed CATX by 66.9 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CATX vs PDSB FAQ

Which is bigger, Perspective Therapeutics or PDS Biotechnology?

PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $91.03M for Perspective Therapeutics (CATX).

Which stock has performed better over the past year, CATX or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons